Fig. 1From: Comparison of ceftriaxone plus macrolide and ampicillin/sulbactam plus macrolide in treatment for patients with community-acquired pneumonia without risk factors for aspiration: an open-label, quasi-randomized, controlled trialFlowchart of study enrollment. Four hundred thirty-three patients were excluded from analysis because of aspiration risks (n = 416), a protocol violation by a physician (n = 13), and the use of immunosuppressive drugs (n = 4). CTRX = ceftriaxone; ABPC/SBT = ampicillin/sulbactam; MITT = modified intention-to-treatment; VPP = validated per protocolBack to article page